DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

Information source: University of Malawi College of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Status Epilepticus; Convulsions

Intervention: intranasal lorazepam (Drug); intramuscular paraldehyde (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: University of Malawi College of Medicine

Official(s) and/or principal investigator(s):
Elizabeth Molyneux, MRCPCH FFAEM, Study Director, Affiliation: College of Medicine, University of Malawi
Shafique Ahmad, MRCPCH FFAEM, Principal Investigator, Affiliation: College of Medicine University of Malawi

Summary

The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emergency compared to our present first line therapy intramuscular paraldehyde.

Clinical Details

Official title: A Randomised Trial to Compare the Efficacy and Safety of Intranasal Lorazepam and Intramuscular Paraldehyde in the Treatment of Convulsions in Children

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: whether the presenting seizure stopped or not with a single dose of assigned anticonvulsant agent within 10 minutes of administration

Secondary outcome:

time from drug administration to cessation of convulsion

frequency of episodes requiring 2 or more anticonvulsant agents

continuous blood pressure and oxygen saturation for 30 minutes post drug administration

seizure recurrence within 24 hours of cessation of presenting convulsion

survival/death

Detailed description: The ideal first line anticonvulsant agent would be one that can be safely and easily given at a primary health care facility. It should be quick acting, have minimal cardiorespiratory side effects and have a relatively prolonged effect and be cheap. No combination of drug or delivery system fully satisfies these criteria. There are no large published studies evaluating intranasal lorazepam in paediatric status epilepticus. Given its favourable pharmacokinetics and potential practical advantages, we wished to assess the efficacy and safety of intranasal delivery of lorazepam compared to intramuscular paraldehyde, our existing first line anticonvulsant agent in the treatment of acute seizures in children.

Eligibility

Minimum age: 2 Months. Maximum age: 12 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Children aged between 2 months and 12 years

- Presenting with generalised convulsions

Exclusion Criteria:

- Any child who had received an anticonvulsant agent within 1 hour of presentation

- Seizure stopped with rapid cooling or treatment of hypoglycaemia

- Features consistent with organophosphate poisoning, hepatic or hypertensive

encephalopathy

Locations and Contacts

Paediatric Emergency Department, Queen Elizabeth Central Hospital, Blantyre, Malawi
Additional Information

Starting date: July 2004
Last updated: July 20, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017